NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 125 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 125 is a fixed-dose combination tablet containing carbidopa, levodopa, and entacapone, indicated for Parkinson's disease. Levodopa is converted to dopamine by DOPA decarboxylase; carbidopa inhibits this conversion in the periphery to increase central availability; entacapone extends levodopa half-life by inhibiting catechol-O-methyltransferase. The three-drug combination provides optimized dopaminergic therapy with extended duration of action.
$0.031BPart D
LOE ApproachingDeclining
Modest Part D presence ($31K) signals a mature, shrinking franchise with minimal commercial expansion opportunity; brand team focus shifts toward defending market share against generic erosion.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STALEVO 125 offers limited growth potential given its LOE-approaching status and modest commercial presence ($31K Part D spending, 14 claims). Career value lies in executing mature-product strategies, defending market share against generics, and developing cost-containment or adherence programs for a declining franchise.
Brand Manager
Worked on STALEVO 125 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.